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ABSTRACT
The growing obesity pandemic has caused diabetes to become one of the world’s
leading health concerns. Diabetic individuals often suffer from peripheral neuropathy,
which is nerve death that typically starts at the extremities and moves from the skin
inward to deeper tissues. This nerve death causes painful symptoms including tingling,
stinging, numbness, and others. Current methods to diagnose peripheral neuropathy by
measuring nerve function are invasive and painful since they target large axons of the
legs; however, by the time the neuropathy reaches the diagnosable axons, it is often too
late for intervention. Although no cures for neuropathy are established, aside from
analgesics for pain, there are options for mitigating worsening of the disease if diagnosed
early enough (for example, glucose control for diabetic neuropathy). There is a critical
need for early detection and diagnosis of peripheral neuropathy as obesity and diabetes
continue to plague the world. Microneedle fabrication is a growing research area,
especially in transdermal drug delivery due to their minimal invasive, pain-free
application. The objective of this project is to design a platform using electrically
conductive microneedles for early detection of peripheral neuropathy. Using these
needles, neurophysiology can be employed to record electrical signal just below the skin
to determine the integrity of the nerves to track neuropathy progression. Thus far,
prototypes of the device have been tested on mice to establish protocols and understand
the hardware and software, with the goal of eventually developing a usable prototype for
a longitudinal study of diseased mice and human clinical studies.
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PROBLEM STATEMENT AND PROJECT GOALS

Diabetes is one of the most prevalent diseases across the world, and peripheral
neuropathy is a common complication of such. The motivation behind this platform is to
ultimately be able to diagnose this nerve death sooner than it currently is done in a
minimally invasive and pain free method. There were several goals of this thesis to get the
platform started and moving towards a direction to ultimately better the standard of care.
The overarching aims of the thesis are as follows:
1. Develop protocols for both the hardware and software obtained to take
electrical recordings in mice.
2. Use well-established nerve models to test and troubleshoot the hardware.
3. Reduce noise of recordings and understand the custom needle electrodes.
4. Develop staining protocols for a new stain, Luxol Blue, that was obtained.
5. Develop behavioral protocols for ways to measure disease progression and
extent.
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INTRODUCTION

Background Information
Obesity is one of the world’s largest pandemics and health concerns of the 21st
century. This disease is characterized by excess body fat and can lead to a number of
health concerns, such as heart disease, joint and limb pain, high blood pressure, diabetes,
and others. It is clinically defined as a body mass index larger than 30 and biologically,
there is more white adipose tissue than metabolically normal.1
There are two different kinds of fats, white adipose tissue (WAT) and brown
adipose tissue (BAT). These types of adipose tissues have metabolic, cellular, and
endocrine functions, and are therefore crucial for energy balance of an organism. WAT
acts as an energy buffer in the body, while BAT is highly oxidative and a main
contributor to thermogenesis, or the production of heat in the body. An excess of WAT is
thought to contribute to obesity due to fat accumulation from energy imbalance, whereas
BAT could have protective effects against obesity. There have been studies aiming to
“brown” white adipose tissue to combat obesity and prevent diabetes, done by either cold
stimulation or pharmacological BAT activation, as adipose is a highly dynamic organ
with an exceptional amount of plasticity.2 However, despite efforts to reverse the effect
of obesity, the pandemic continues to grow, and is a worldwide concern, as shown in
Figure 1.3
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Figure 1. Percentage of adults defined as obese [Body Mass Index (BMI)>30%] as of
2016. Adapted from Ref [3].
Diabetes is one of the world’s largest health issues, and is a major disease
stemming from obesity. As defined by the Center of Disease Control and Prevention,
diabetes is, “the condition in which the body does not properly process food for use as
energy”.4 Glucose, or commonly called “sugar”, is an essential energy source in the body
for many metabolic pathways; however, people with diabetes are unable to properly
digest glucose. Insulin is a hormone that enables glucose to get inside the cells of our
body for energy, and the pancreas is the primary manufacturer of this hormone.
Individuals with diabetes either do not make enough insulin to remove glucose from the
blood, or the insulin the pancreas produces does not function at full capacity. As a result,
glucose accumulates in the blood and is not taken in by cells for energy. This
accumulation can result in serious health effects, including, but not limited to, heart
disease, neuropathy, blindness, kidney failure, and even death.4
There are two types of diabetes: Type 1 and Type 2. Type 1 diabetes is less
common but related to autoimmune, genetic, and environmental factors. Type 2 is much
3

more common, comprising about 90-95% of diabetes cases, and has multiple risk factors
including aging, obesity, family-related diabetes, race, and more.4 Both types of diabetes
are typically caused by the loss of β-cell mass, either physically or functionally. β-cells
are crucial for the response of fluctuating insulin demand. They produce insulin and are
significantly regulated by glucose to induce metabolic pathways, insulin gene
transcription, and insulin secretion. As a result, glucose is essential for normal β-cell
function, regulation, and maintenance. However, in diabetes, the functionality and/or
quantity of these cells is compromised, resulting in obesity and insulin resistance.5
The differences between Type 1 and Type 2 diabetes relates to the mechanism by
which glucose is improperly digested and the process in which the β-cells are lost. For
instance, Type 1 typically lose β-cells due to an autoimmune process, while Type 2 is the
result of insulin resistance.6 Essentially, in Type 1 diabetes, the patient does not produce
enough insulin, so the pathways that allow glucose uptake into the cells is inhibited. In
Type 2 diabetes, enough insulin is produced, but the cells are resistant to the hormone
because the insulin receptor is insufficient. This is illustrated in Figure 2, which details
the differences between Type 1 and Type 2 diabetes and the way that each type affects
the body. In general, there is no cure for diabetes, but obesity-related Type 2 treatments
can include diet regulation and physical exercise.4
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Figure 2. A schematic detailing the differences between a normal, Type 1, and Type 2
diabetic individual and how insulin and insulin receptors play a role in disease.
One of the quintessential symptoms of diabetes is neuropathy at the peripheral
limbs, such as an individual’s hands and feet. Peripheral neuropathy is the result of
damage to the nerves, which can cause things like weakness, numbness and pain; this
pain can include stabbing, burning or tingling from the extremities. It is estimated that at
least 22 percent of people with diabetes have moderate to severe peripheral neuropathy,
and this percentage is only growing.7 From the 22 percent of individuals with diabetes
that will be affected by neuropathy, the current state of care is that there is no cure, just
analgesics for pain.7,8
Neuropathy can be the result of nerve death associated with nerve axons, myelin
sheath, or both, and can involve motor, sensory, or autonomic nerves.9 In addition to the
types of nerves that are involved with peripheral neuropathy, the size of nerve fibers,
either small or large, can be used to categorize neuropathy. When the nerves begin to die
or become damaged, the communication between neurons is affected, which can lead to
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more damage down the road. An individual can either have genetic neuropathy or can
acquire this nerve damage over time due to trauma, vascular disorders, systemic diseases,
infections, vitamin imbalances, and others. The nerves can become damaged when there
is compression of the nerves at the periphery with overuse, repetitive stress, or when
there is impeded blood flow to these neurons. A lack of blood flow to the extremities can
come from inflammation or blood clots, which ultimately limits oxygen availability and
results in nerve damage or death.10 Other molecular factors that result in nerve death
involve toxins or an imbalance of nutrients, such as vitamins, that are critical to healthy
nerve function.10 Again, there are ways to monitor and alleviate symptoms, but there is
no treatment to completely reverse the effects of nerve damage and death associated with
peripheral neuropathy.
In general, peripheral neuropathy is organized and categorized based on what type
of nerve fibers are involved, which includes things like the size and how fast nerves
transmit signals along the axon. There are three types of peripheral nerves: somatic motor
neurons, somatic sensory neurons, and autonomic neurons. The somatic sensory and
autonomic functions are based on whether the nerves are involved in things like touch,
pain, temperature, blood pressure, sweating, and heart rate. There are also classifications
based on size and diameter of the nerve fibers that are similarly used to classify nerves.
A-alpha and A-beta nerve fibers are myelinated and have a large diameter. The function
of these nerves is to carry out motor functions and one’s sense of touch.11 Medium-sized
diameter nerve fibers that are myelinated are A-gamma nerve fibers which function to
transmit the motor function to muscle spindles. Small-diameter nerve fibers that are
myelinated and unmyelinated are categorized as A-delta and C nerve fibers, respectively.
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These small-diameter fibers carry pain and temperature sensations, as well as transmitting
the autonomic functions that are involved in small fiber neuropathy typical with nerve
death associated with diabetes.11
There are several different types of neuropathies, and diabetic peripheral
neuropathy (DPN) is just one broad-encompassing term. One type of DPN is small fiber
neuropathy (SFN), which occurs in the small diameter fibers that are both myelinated and
unmyelinated. In this type of neuropathy, the large nerve fibers are relatively unaffected
by neuropathic pathologies, leaving the small nerves in the hands and feet in pain, but
making detection of neuropathy difficult. In SFN, the small diameter fibers such as Adelta and C nerve fibers, which are both myelinated and unmyelinated, are affected
directly. This leaves the larger types of peripheral nerve fibers like A-alpha and A-beta to
be healthy and unaffected.11 There are several methods that are used to diagnose SFN, but
the techniques are typically insufficient because of the large axons that are targeted, but
not affected, in this type of neuropathy.
Addressing small fiber neuropathy in the clinical setting is difficult to interpret
and classify. It is defined, loosely, by small fibers with neuropathic pathologies that are
more severe compared to the large fiber pathologies. For addressing the severity of SFN
qualitatively, a neurologist can look at the extent of dysesthesia.11 Dysesthesia is a
disruption of sensory neurons that can lead to sensations of pain, itchiness, burning, or a
lack of sensation in general.12 Other criterion physicians may use are those that relate
specifically to neurological damage in small nerve fibers. This criterion can include a loss
of stimuli perception in the extremities like the toes, a loss of the ability to perceive the
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environment and the position in that environment (i.e. location and movement), any
weaknesses of distal limbs, and the general strength of reflexes.11
Similar to DPN and SFN, the adipose cells can also develop neuropathy.
Peripheral nerves innervate adipose tissue all throughout the body to communicate with
the brain, so adipose neural tissue is also prone to neuropathy. When the nerves die back
from the adipose, control of metabolic function is lost, which progresses the obesity with
growing adipocyte counts and increased adipose tissue mass. It has been shown and
Figure 3. A schematic of peripheral neuropathy nerve death moving from the skin inward
as the disease progresses. Reproduced from Magdalena Blaszkiewicz.
measured that through analysis of both human and mouse tissues, neuropathy does occur
at the nerves innervating WAT, so adipose neuropathy is directly related to the growing
diabetes epidemic.13 As a result, knowledge of adipose neuropathy is critical for
understanding peripheral neuropathies associated with obesity and diabetes.
Additionally, adipose neuropathy is evidence that nerve death moves from the
skin inward, affecting underlying tissues such as subcutaneous white adipose tissue

(scWAT). If adipose neuropathy affects adipose metabolic function and control, then
nerve death continuing to the underlying tissue could prove to be a mechanism of pain
and disease progression.13 The dying back of nerves in peripheral neuropathy is
illustrated in Figure 3, where the sensory skin nerves are affected first and die back to
underlying adipose tissue.
8

Despite having no cure, the prevalence of diabetes is not decreasing; in fact, it is
growing. As shown in Figure 4, there are millions of people worldwide affected by
diabetes, and the projected numbers of individuals affected with diabetes by 2040 grows
in every continent and region across the globe.14

Figure 4. The worldwide prevalence of diabetes across the globe, with the number of
individuals affected as of 2015 for each country, and the projected the number of
individuals affected in 2040. Reproduced from Ref [14].
With the rising number of diabetic individuals, diagnosis, characterization, and
quantification of peripheral neuropathy is in increasing demand because current methods
are generally insufficient.

Diagnostic Tests of Neuropathy
The current standard of care for neuropathy diagnosis involves multiple tests,
some of which are exceptionally invasive and tedious. The prevalence of neuropathy is
growing because individuals are often either unable to diagnose neuropathy, or it is
diagnosed at a time where the disease has progressed too far to intervene in an efficient
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manner. Additionally, there are currently no cures for neuropathy, nor any way to halt the
progression of nerve death. The only way to mitigate pain is with analgesics, and
progression may be slowed with and glucose regulation for diabetic individuals.13
However, there is a clear clinical need for diagnosis of peripheral neuropathy as current
methods are inadequate.
One test a neurologist can perform is an electromyography (EMG), which is
essentially a test of the connection between one’s nerves and the surrounding muscle.
This test can be informative to determine if there are problems with nerve signal
transmissions or if there is nerve or muscle dysfunctions. An electromyography requires a
needle to penetrate the skin to get directly to the nerves, particularly large axons for a
larger target, to record how much electric signal is flowing through the muscle.15 When
an individual undergoes this procedure, a small needle or electrode is inserted in the area
of interest and an oscilloscope is used to display the electrical activity of the tissue, as
shown in Figure 5.16 Recordings from the patient would be taken while at rest, during a
slight contraction, and during a full contraction of the muscle, such as completely
extending or bending the knee. The electrical activity recorded is compared to healthy
individuals to determine if there is some sort of nerve disfunction, as the neuropathic
individual would have a weakened response during nerve stimulation of muscle
movement.15
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Figure 5. A schematic outlining potential needle and electrode placement for an EMG
test. Reproduced from Ref [16].
A test that is typically coupled with an electromyograph to diagnose neuropathy is
a nerve conduction velocity (NCV) test. Surface patch electrodes are placed on the skin
for stimulation, and others are placed at different known locations to measure the
electrical impulse downstream, as shown in Figure 6.17 The speed of nerve transmission
is determined from this test and can be telling of decreased nerve conduction, which can
yield information about axonal myelination, or the lack thereof. The electromyograph can
help understand the possibility of muscle innervation on these tests, so, collectively, an
EMG and NCV can be indicative of general nerve health by comparing the speed of
firing or pattern (i.e. latency time) associated with the nerve to healthy individuals to see
if these factors are affected by neuropathy-associated nerve damage.15
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Figure 6. Nerve conduction velocity procedure setup to show potential surface patch
electrode placement. Adapted from Ref [17].
An EMG and NCV test can be useful for extensive nerve damage, but both are
invasive and not a guaranteed diagnosis of small fiber neuropathy (SFN). The area of
needle penetration for an EMG can be sore for several days afterward, similar to the
feeling of receiving a shot. Multiple needles may be necessary for diagnosis, so the
discomfort is more than just a single needle in one spot. Bleeding and bruising can also
occur, and the use of needles poses the threat of infection.15 In addition, receiving these
tests is inconvenient, as the patient must see a neurologist or other specially trained
individual; these specialized people are often booked many months in advance.
Additionally, the results of these tests vary with age; younger individuals generally have
less myelination than a healthy adult, so the nerve conduction speed in younger people is
typically slower. Therefore, bridging the gap between age and actual neuropathy-like
symptoms is a potential limitation of these tests. The electrodes used for an EMG and
NCV are sensitive to noise and temperature, among other factors, which could influence
the diagnosis. If the temperature of one’s skin is colder, then the nerve conduction speed
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and muscular electrical activity can be hindered and affected in a way that could indicate
neuropathy, but in a healthy individual.18
Nerve conduction velocity tests are the typical diagnostic tools, but NeuroMetrix
has developed a less invasive device to evaluate diabetic peripheral neuropathies called
the DPNCheck. The NCV of the sural nerve, the main nerve through the calf, and the
response to stimulation is measured and analyzed for neuropathy diagnosis. This device,
shown in Figure 7, is fairly sensitive to changes in the functionality of the sural nerve.19
However, by the time the neuropathy spreads from the feet to the calf nerves that are
measured with this device, it is too late to treat. Additionally, the progression of
neuropathy to the calves is significantly more painful for the diabetic individual, and such
pain will only continue to worsen without earlier treatment.

Figure 7. DPNCheck by NeuroMetrix is a device targeted at measuring sural nerve
conductance. Reproduced from Ref [19].
Another tool that is currently used to diagnose neuropathy is a skin biopsy. Skin
biopsies are typically used for small nerve fiber neuropathy, which is one of the most
difficult to distinguish and recognize. When a patient is receiving a skin biopsy, the area
is often numbed with lidocaine and the doctor removes a sample of skin. These samples
13

can be taken from any part of the body, such as the fingers and toes, unlike an EMG or
NCV. The collected skin sample is then analyzed with bright-field
immunohistochemistry or indirect immunofluorescence to analyze the small nerve fibers
from that tissue.20 When sectioned and stained with PGP 9.5, a pan-neuronal marker, the
analyst would be able to observe the nerves present and do necessary calculations on the
tissue to diagnose peripheral neuropathy, such as density counts per area.20
Although the pathologist that receives the stained sample could visualize the
nerves, this technique is not ideal for diagnosing small nerve fiber neuropathy. Skin
biopsies are very invasive, as they require a skin sample to be scraped and removed from
the patient.20 Additionally, this technique only assesses morphologies of the nerves
instead of function. Observation of the nerves in the biopsy that are stained can give
subjective results if there are discrepancies in opinions of the viewers based on the small
sample size taken. To really diagnose and assess the extent of neuropathy, ideally, one
would be able to address function and morphology.
Yet another method that is used for neuropathy diagnosis is microneurography.
Microneurography is used to directly record and measure sympathetic action potentials.
This technique employs skin-surface electrodes, so it is minimally invasive, and can
measure peripheral nerve conductance and assess the function of small nerve fibers. The
spectrum of signals collected is relatively broad, so multiple nerve types are
distinguished. However, microneurography fails to record sympathetic activity for
diabetic individuals due to potential sensitivity limits. Therefore, this could significantly
limit the types of patients that can benefit from this diagnostic tool.21,22
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A relatively new approach of diagnosing peripheral neuropathy is to address
sudomotor function, or how well an individual’s sweat glands are functioning. The thin,
unmyelinated C fibers innervate sweat glands, and these are the types of fibers that are
more greatly influenced in diabetic neuropathy and SFN. C fibers are affected early in
diabetes and can continue to worsen as the disease and neuropathy progresses. Therefore,
measuring sweat gland dysfunction could be useful to determine the function and
integrity of the innervating and surrounding C fibers.23 One device, named Sudoscan, has
been engineered to diagnose sweat gland dysfunction. This method is minimally invasive
and pain free, gives a functional assessment of the small fibers, and can detect early
neuropathy before symptoms arise.23
The Sudoscan device consists of two electrodes that one’s hands or feet are placed
on. When an individual has healthy sweat gland dysfunction, and the small fibers are
innervating these glands, chloride ions are secreted and released to the surface.24 The
electrodes for the Sudoscan device measures chloride ion conductance, so a high
conductivity would indicate more sympathetic innervation; therefore, the progression of
prediabetes and neuropathy can be determined based on chloride conductivity.24,25
Although this is an indirect functional assessment of the small nerve fibers, peripheral
nerve conductance cannot be measured, and Sudoscan does not provide an analysis of
many nerve types that can be affected with peripheral neuropathy.
Despite several different types of diagnostic techniques and treatments, these tend
to be insufficient in accurately addressing peripheral neuropathy. Methods such as skin
biopsies, nerve conduction velocity tests, and an electromyograph are invasive and can
cause pain for the individual. Additionally, tests like NCV, EMG, and the DPNCheck
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device can measure nerve conduction velocities of large axons; however, by the time the
neuropathy reaches these points, it is often too late for intervention and alleviation of the
pain. Other methods, such as Sudoscan, are indirect measures of neuropathy and could be
insensitive to small changes as the neuropathy progresses from the skin inward.
Therefore, there is a clear need for a noninvasive and effective measure of peripheral
neuropathy detection at the early stages of disease that emphasizes on addressing nerve
functionality. A promising method for this diagnostic platform is microneedles.

The Growing Use of Microneedles
Microneedles are an emerging technology in biomedical engineering.
Microneedles are arrays of small, minimally invasive needles that have various uses in
many industries, such as for transdermal drug delivery (TDD). Microneedles can be
hollow to administer drugs to bypass the tough epidermal layer, making the speed of drug
delivery directly into the subcutaneous tissues greatly enhanced, but also the amount that
is administered to the individual. A general schematic of TDD is illustrated in Figure 8,
where small drugs can be released directly into the body through the hollow microneedles
due to increased skin permeability and more direct drug administration.26

Figure 8. A schematic illustrating transdermal drug delivery with a microneedle array.
16

Microneedle arrays are preferred over single needles because they are painless
and minimally invasive. There is increased microneedle use in research because there are
a variety of materials and structures that they can be made of, allowing for very diverse
uses. There are microneedles made of a variety of materials including, but not limited to,
silicon, glass, ceramic, hydrogel, polymer, and metal. The length of the needle can also
be changed by etching and sawing the needles in a particular fashion.27 Additionally, the
needles can be coated with insulation or other materials to further optimize their use in
research. Therefore, there is a growing application of microneedles because they are
relatively customizable due to the characteristics that can be modified, and hold promise
for many different applications.
In the creation of a device for early diagnosis of peripheral neuropathy,
microneedles seem promising. Using microneedles to record electrical signals is a
relatively novel approach as many researchers and industries are not conducting these
kinds of experiments. However, coating or making microneedles in a conductive material
enables them to be used as electrodes, which have the ability to measure electrical
signals. Biomedical companies such as BlackRock Microsystems sell arrays to measure
nerve conductance, but typically for brain recordings.28,29 Many experiments that involve
microneedles recording electrical signals in the body are done with nerves in the central
nervous system like the brain and spinal cord, rather than the peripheral nervous system.
Blackrock Microsystems also creates a slant array for peripheral nerve data, but similar to
the diagnostic tests for neuropathy, these arrays are targeted for implantation in nerves
like the sciatic and sural nerves in the leg, rather than small fiber nerves at the extremities
that are affected by peripheral neuropathy first.30 Therefore, the design of this novel
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neuropathy diagnosis device is to use microneedles to record electrical signals from the
extremities to determine the functionality of nerves. To do so, an understanding of
neurophysiology and what can be affected by neuropathy is necessary.

Neurophysiology Overview
Neurophysiology is a branch of neuroscience and physiology that focuses on the
physiology and functioning of the nervous system; this field of study often involves
electrophysiological or other biological tools. Neurons function by establishing
electrochemical gradients across the cell membrane to generate action potentials;
essentially, neurons make use of an established transmembrane voltage difference. In
current nerve conduction studies, typically the voltage of an action potential or the speed
of transmission is measured. It is known that the resting membrane potential of a neuron
is about -40 to -90 mV. When a neuron is stimulated or information via synaptic
terminals is sent, the membrane potential can depolarize, resulting in an action
potential.31 Measuring the amplitude of voltage from the action potential is one way in
which researchers test the functionality of nerves because it can be done locally.
Additionally, an action potential travels down the axon at a particular speed for that
neuron, depending on the extent of myelination of that nerve. Determining any changes
in action potential propagation velocity is another way one can assess nerve function,
especially across a larger area. Therefore, voltage amplitude and velocity are two
characteristics that are employed in neurophysiology because these characteristics give
information both locally and across a larger portion of nerve.31
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It is known that neuropathy can decrease the amount of myelination around a
nerve.9 The myelin sheath is an insulating layer around the nerve that speeds up nerve
transmission. In a neuropathic individual, the amount of nerve myelination is less, which
would ultimately slow down the nerve conduction velocity. In a study of 500 diabetic
individuals, the motor and sensory nerve conduction in patients with diabetic peripheral
neuropathy was measured and compared to those of healthy people. It was concluded that
distal motor latency (DML) in the median and common peroneal nerves in symptomatic
diabetics was longer than that of asymptomatic diabetics, potentially indicating less
myelination. The compound motor actional potential (CMAP) amplitude in these same
nerves was also lower in the diabetic individuals suffering from peripheral neuropathy
compared to diabetic individuals with no neuropathic symptoms, as shown in Figure 9.32

Figure 9. Motor nerve conduction in diabetic patients with and without peripheral
neuropathy and in control subjects. Figure 9A is the Distal motor latency (DML) and
Figure 9B is the compound muscle action potential (CMAP) between symptomatic groups
(SG), asymptomatic groups (ASG), and control groups (NC). Reproduced from Ref [32].
Sensory nerve conduction studies were also done in this study of 500 diabetic
individuals. It was determined that sensory nerve action potential amplitude (SNAP) and
sensory nerve conduction velocity (SCV) in the diabetic groups (symptomatic and
asymptomatic) was lower than that in healthy controls. Furthermore, in the symptomatic
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diabetic group, the SNAP and SCV of the median, ulnar, posterior tibial, and common
peroneal nerves were significantly lower in the symptomatic group compared to the
asymptomatic group, as detailed in Figure 10.32

Figure 10. Sensory nerve conduction in diabetic patients with and without peripheral
neuropathy and in control subjects. Figure 10A illustrates the sensory nerve conduction
velocity and Figure 10B illustrates the sensory nerve action potential between
symptomatic groups, asymptomatic groups, and control groups. Reproduced from Ref
[32].
Therefore, while conducting neurophysiology tests with the designed microneedle
array, the latency, action potential amplitude, and conduction velocity are all aspects that
should be considered when configuring electronics and analyzing data. These three
characteristics are factors that will be affected by peripheral neuropathy; as a result,
differences in electrical signals of peripheral nerves between diabetic and control groups
can be compared to obtain an early diagnosis and track the progression of disease. The
expected neurophysiological results of the latency, conduction velocity, and the action
potential amplitude of a diseased versus healthy individual is illustrated in Table 1.
Table 1. Summary of expected neurophysiological changes between a healthy and
diabetic individual, relative to each other.
Characteristic
Latency
Conduction velocity
Action potential amplitude

Control

Diabetic/Neuropathic

↓
↑
↑

↑
↓
↓
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Using Mice as a Model of Disease
There are several organisms that are used in research and industry to conduct
preclinical tests or to model human mechanisms, including mice, zebrafish, rats,
monkeys, fruit flies, and more. Each organism has its own benefits depending on the area
of study; for instance, zebrafish are useful in studying the immune system due to similar
human cell types, such as neutrophils. However, mice are one of the most common
research animals, and there are several reasons why. Most importantly, mice and humans
have many of the same genes, and humans and mice develop in the same way from an
egg and sperm. As a result, the organ systems of mice are closely related to that of
humans, and this similarity allows researchers to study biological mechanisms and the
effects on the entire body. Another reason the mouse is used is because of their lifespan.
Mice live long enough to be able to easily conduct longitudinal studies of chronic
diseases or aging, but short enough to be reproducible. The small size of mice makes
them easy to house and maintain for the entirety of their life.33 Also, much is known
about mice and their genome, so it can be easily manipulated to observe changes, and
different strains can be more effective than others, depending on the study’s purpose.
Therefore, in the early stages of prototyping and designing the device, mice will be used
as a model of disease.33
In the Townsend Laboratory, mice are used as a model of disease as they develop
neuropathy either genetically or through administration of a high fat diet. The genetically
induced neuropathy model is a BTBR ob/ob leptin-deficient diabetic mouse. The BTBR
model develops severe Type 2 diabetes because the animals are genetically insulin
resistant. This insulin resistance and other factors associated with diabetes are developed,
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making the BTBR ob/ob mice a model for disease progression as the diabetes advances
over the lifetime of the mouse.34 Additionally, the BTBR ob/ob model can be used to test
the first prototype of this diagnostic device as these genetically altered mice do develop
peripheral and adipose neuropathy.13
Mice develop diabetes not only genetically, but also environmentally through the
administration of a high-fat diet. In a study where mice were fed a high-fat diet for 12
months, the researchers found diabetic morphologies related to insulin levels, glucose
tolerance, and more. Therefore, mice can develop diabetes, and consequently peripheral
neuropathy, while being fed a high-fat diet similar to humans and the Type 2 diabetes
epidemic.35 As a result, the designed early-diagnosis prototype is using mice for initial
tests and optimization, and eventually as a method to track disease progression.
Initially, much work has gone into creating and optimizing a device to use for a
longitudinal study in the future. The electronic components used must be set up
appropriately to reduce noise but maximize reproducibility. Protocols, standards, and
various tests are described and conducted to learn about the needles, software, and
working with neurophysiology in a practical sense to develop a point-of-care diagnostic
device to translate to human clinical trials.
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PROTOCOL DEVELOPMENT

With the aforementioned project goals, most of the work done for this thesis was
developing an appropriate protocol to use the new equipment. BIOPAC, the recording
hardware and software, was new to the Townsend Laboratory; therefore, it was essential
to get familiar with it and develop a working protocol to take recordings. To do so, much
trial and error was done with the electrodes using saline agar solution and horseshoe crab
tissue. The amplifier settings were altered to see how the resulting current was affected in
many different experiments to further understand the recording signals and how to
manipulate the hardware. Additionally, much work was put in to understand how to use
the AcqKnowledge software that is used to look at and analyze the signals. All recordings
and experiments conducted in this thesis used the developed protocol after much
troubleshooting and manipulation had been done.
Furthermore, behavioral protocols to test for disease progression and extent were
developed and tested. A cold plate test and an acetone test will eventually be used in a
longitudinal study in mice to behaviorally measure neuropathy, and these tests were new
to the Townsend Laboratory. After Institutional Animal Care and Use Committee
(IACUC) approval, these protocols we engineering to eventually be used as a neuropathy
test.
Another protocol that was developed as part of this thesis work was to use Luxol
Fast Blue. This is a stain for myelinated nerves, and again was new to the Townsend
Laboratory. In order to optimize a staining procedure, many tissues, such as muscle,
adipose, and sciatic nerve, were stained. All these tissues were stained multiple times
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with multiple different incubation times in order to optimize the protocol to be used. As a
result, a large part of this thesis work accomplished its goals for protocol development
that will be used for experiments and results elaborated on below, but also in the future
for comparison methods of neuropathy.

24

MATERIALS AND METHODS

Materials and Hardware
§

BIOPAC MP160 Data Acquisition Hardware, Part No. MP160WSW

§

BIOPAC AcqKnowledge® 5 Acquisition and Analysis Software

§

BIOPAC HLT100C Transducer module

§

BIOPAC AC150A Power Supply

§

BIOPAC MCE100C Micro Electrode Amplifier (x4)

§

Alligator clips

§

Laptop

§

VisionTek USB Docking Station

§

Power strip and power supply

§

Mini hook leads

§

Faraday cage

§

Dissection microscope with light

§

Custom Microneedles*

§

Microprobes 0.5 MΩ commercial platinum iridium electrode

§

Natus Ultra Disposable Stainless-Steel Subdermal Needle Electrodes

*Due to current intellectual property and the patent process, certain aspects and
dimensions of the needles, as well as some specifics of the work conducted must be
omitted
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Methods
I. Animal Subjects
Animals used in this work include Limulus polyphemus, or horseshoe crab, under
the assistance of Dr. Leonard Kass. Limulus tissue was used to validate the recording
setup and electronics by using a well-established and well-known nerve model. Mice
were used with IACUC approval and regulations, detailed in Appendix A. During basal
recordings tests (no stimulation), mice were anesthetized with 1.5% isoflurane in pure O2
at a flow rate of 1 L/min and euthanized after nerve recordings by trained personnel.

II. Experimental Setup
All recordings were taken in the Faraday cage illustrated in Figure 11. The
BIOPAC hardware, laptop, and USB docking station are all positioned on a table next to
the Faraday cage to minimize the length of wires between the recording area and the
hardware, therefore reducing noise in the recordings. Electrodes that are being used for

Figure 11. Recording setup with the Faraday cage, BIOPAC hardware, and the laptop
with the necessary software. Reproduced from Brooke Villinski.
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recording are connected to red mini-hook leads, detailed in Figure 12, and there are
marked ground and stimulation electrodes that come from the respective black leads.

Figure 12. Red mini-hook leads that hold all differential recording electrodes.

III. BIOPAC Protocol for Collecting Recordings
There are many functions of the BIOPAC software and hardware, and it can
execute multiple things both in the collection and analysis of data. There are recordings
with and without stimulation, both of which are used to collect the data presented in this
thesis.
First, to use the software, turn on the VisionTek external USB connector, the
laptop, and the BIOPAC MP160 hardware. Insert the teal AcqKnowledge USB into the
VisionTek connector to have the hardware communicate with the software and laptop.
When the computer is turned on, open the AcqKnowledge icon on the desktop to open
the recording software. Create a new experiment, and then open an existing graph
template file (GTL). The files are named according to their settings, such as the
stimulation voltage amplitude, duration, or for simple basal recordings. Opening this
GTL will load the saved settings within the file. Before recording, ensure amplifier
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settings are appropriate on the MCE100C hardware. The standard settings for recording
with and without stimulation are detailed in Table 2, unless specified otherwise.
Table 2. Standard MCE100C amplifier settings.
Setting

Value on MCE100C
Amplifier
1000x

Gain
Low Pass (LP)
Filter
High Pass (HP)
Filter #1
High Pass (HP)
Filter #2

3kHz
100kHz
0.5 Hz HP

Inside the Faraday cage, the alligator hook leads are set up for recordings by
placing electrodes in the desired tissue. The recordings are from a differential amplifier,
so two electrodes are put into the tissue, with a ground to reduce noise. A stimulation
electrode can also be put into the tissue close to the recording electrodes, but care should
be taken to ensure all leads are appropriate for their purpose (i.e. differential recording
and stimulation electrodes lead to the amplifier at the correct position). After electrodes
are inserted, the Faraday cage can be closed, and “Start” can be selected on the
AcqKnowledge software. This setup was used to record for all experiments involving
recordings, with and without stimulation. Different electrodes were incorporated to
compare among needle types, but the general configuration of the electrophysiology rig is
the same. A detailed procedure is outlined in Appendix B.
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IV. Cold and Hot Plate and Acetone Testing
Part of the platform is to ultimately record electrical signals from the mouse and
relate the results to already-established measures of neuropathy. Currently, hot and cold
surfaces are used to test for the presence of neuropathy. If a subject is diabetic, the
response time will either be slower or completely diminished when exposed to hot or cold
temperatures compared to a healthy individual. Additionally, chemical tests, such as
acetone, are used for similar qualitative responses to the acetone being applied to the hind
paw. In a future longitudinal study with the designed needle array, all three tests will be
used to relate electrical signals to the progression of neuropathy. These tests were new to
the Townsend Laboratory, so protocols had to be revised and established to conduct these
tests. Therefore, part of the project included the development of these protocols. The
established protocols for the cold plate and acetone tests are shown in detail Appendix C.
Also, in addition to the protocols, a template for recording data for the cold plate test was
established. This template is also detailed in Appendix C.
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RESULTS

I. Using Limulus Tissue to Validate the Electrical Setup
Limulus tissue is a well-established nerve model, so the initial experiment was to
validate the electrical setup and the wire configurations. Additionally, BIOPAC was a
new software, so a protocol needed to be established on how to use the hardware. Dead
Limulus tissue was obtained and the custom needles to be used in the future array were
used for stimulation of the tissue. Standard commercial Microprobes electrodes were
used for differential recordings, and each needle electrode was positioned as detailed in
Figure 13. In the experiment, electrodes were moved from one position, termed Setup 1,
to further apart in Setup 2 in Figure 13 to measure differences in recordings amplitudes.

Stimulation

Ground

Figure 13. Electrode setup in dead Limulus tissue to validate electrical configurations
and observe differences when electrodes are separated by two different distances.
Sample recordings are illustrated in Figure 14. Setup 1, where the recording
electrodes were closer together, has a higher signal amplitude compared to Setup 2,
where the recording electrodes were further apart. This is what was expected as when the
needles are closer together, less signal is lost to the surroundings. This experiment was a
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proof-of-concept test to ensure recording electrodes, wires, and the BIOPAC hardware
was set up appropriately, and to become familiar with how to use BIOPAC. A protocol,
detailed in Appendix B, was established as part of this test. Therefore, it can be
concluded from this experiment that moving forward, the software and hardware setup is
set up appropriately to measure recordings in tissues.

Figure 14. Sample recordings from dead Limulus tissue with electrodes placed in
different positions in Setup 1 and Setup 2. Setup 1 has a higher voltage amplitude
compared to Setup 2, which is expected given that Setup 1 needles are closer together.

II. Using Limulus Tissue to Learn How to Stimulate with the Software
Basal and stimulated recordings are desired for the final prototype of the device,
so learning how to stimulate with BIOPAC was essential. The purpose of this experiment
was to further develop a protocol and become familiar with stimulation using the
software. Again, Limulus tissue was used because of its reputation as a well-established
nerve model. Recording electrodes were placed into two ends of the tissue, with a ground
and a stimulation electrode in between, detailed in Figure 15. The purpose of this
experiment was to test different stimulation voltage magnitudes to measure any limits in
voltage signal, to, in the future, stimulate with the lowest possible voltage to minimize
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risk to the animal. Four stimulation voltage amplitudes were tested: 0.05 V, 0.1 V, 0.2 V,
and 0.4 V.

Figure 15. Electrical setup used in the experiment to measure different stimulation
voltage levels.
Sample recordings from the experiment with different stimulation voltages are
detailed in Figure 16. As the stimulation voltage increased, the amplitude of the signal
also increased, as shown in Figure 16A, 16B, and 16C. From Figure 16C and 16D, there
is a potential saturation in the signal, as there is no observable difference between 0.2V
and 0.4V stimulation. However, the results are still consistent with what one would
expect with an increase in the stimulation voltage; therefore, a method to stimulate with
the BIOPAC hardware and software was established and incorporated into the protocol in
Appendix B to, in the future, stimulate animal subjects.

Figure 16. Sample recordings from the experiment with stimulation voltages of A) 0.05V,
B) 0.1V, C) 0.2V and D) 0.4V. As the magnitude of stimulation increased, so did the
signal, until a plateau at 0.2V and 0.4V.
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III. Testing the First 3D Printed Microneedle Array
(array designed and printed by Julia Towne)
The first prototype of a device was designed and printed, so the purpose of the
experiment was to test this design and its dimensions on a euthanized mouse. A mouse
was euthanized and basal recordings were taken from the shaved scWAT area, with the
electrodes positioned in the image in Figure 17. The dimensions of the needle array were
3.5cm x 1.5cm with needles spaced by 5.1 mm apart, with a penetration depth of 1 mm.

Figure 17. Image of the mouse and needle array positioning that was used in the
experiment to test design dimensions and recording from a needle array. Array designed
and printed by Julia Towne.
In this experiment, basal recordings were taken by moving one differential
recording electrode around all nine different needle positions in the array. The needle
positions were labeled according to Figure 18, and all combinations of needles in relation
to Electrode 1 were tested to determine if noise levels were appropriate to distances
between needles; again, this was to show that the BIOPAC software and hardware was
positioned appropriately and to demonstrate how recordings from an array could be done.
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Figure 18. Electrode labels on the mouse that were used in the experiment to test
different recording positions.
Sample recordings from this experiment are shown in Figure 19. When the
electrodes were moved to the same needle, Needle 1, the signal canceled out as expected
in Figure 19A. When the electrode was moved to positions 1 and 2, essentially right next
to each other, there was an increase in signal, as shown in Figure 19B. The recording
electrodes were then moved as far apart as possible within the array, to positions 1 and 9.
As expected, when the needles were moved further away, the noise increased, as detailed
in Figure 19C. The noise was expected to increase because the recordings were just basal
recordings, so the amount of tissue between the electrodes increased, thus increasing the
amount of noise. Therefore, from this experiment, it could be concluded that a needle
array is feasible to obtain recordings from different positions within the array.
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Figure 19. Sample recordings from the first printed device. Electrodes were moved to A)
Positions 1 and 1, B) 1 and 2, and C) 1 and 9. As the distance between needles increased,
the amount of noise also increased, as expected.
However, another purpose of the experiment was to test the overall design and
dimensions of the device. The dimensions of the array that were printed were concluded
to be too large moving forward, because the needles often moved out of the skin. The
spacing between needles, 5.1mm, made the array to cover an exceptional amount of the
entire mouse, even though the scWAT was the target area. The large rectangular design
on the rounded mouse made needles leave the surface of the skin, causing issues with the
needle staying positioned on the mouse and needles continuously penetrating the skin.
Another aspect of the array that could better facilitate needle penetration is increasing the
depth of needle exposed. In this design, 1mm of needle was exposed to pierce the skin. In
future prototypes, this could be increased to 2mm to go deeper into tissue and to help
with maintaining needle penetration for the entire experiment. Additionally, in Figure 17,
the design featured a large cylindrical rod from the center of the electrode. This rod was
incorporated into the design with the idea it would help apply even pressure to the array
when the needles were being inserted into the mouse. However, the rod was unnecessary,
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and even obstructed the movement of some electrodes around the array. As a result, from
the initial tests of the device, can be concluded that the dimensions of 3.5cm x 1.5cm
with needles spaced by 5.1 mm apart and a penetration depth of 1 mm is not suitable for
future designs. The array should be shortened with needles positioned closer together,
and with the rod from the center removed. This experiment was important and
informational for determining and testing design dimensions to move forward with
designed and printed prototypes.

IV. Basal Mouse Recordings to Compare Needles to Commercial Needles
The first prototype of the design uses needles that are not currently used for
recording electrical signals in tissue. As a result, it is essential to learn about these
needles and to compare these needles to commercially available electrodes that are used
for neural recordings. The purpose of this experiment was to use an anesthetized mouse
to obtain basal recordings of the subcutaneous adipose tissue using both the design
needles and commercially available needles to compare signals between the two.
Amplifier settings were also modified with the needles in the tissue during the
experiment to further understand how high and low pass filters affect signal.
First, one recording custom needle was inserted into the scWAT of the mouse, as
shown in Figure 20. The other differential recording electrode, not shown in the figure,
was inserted in the base of the tail. Recordings were taken with the standard amplifier
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settings but were changed throughout the procedure to try and reduce noise of the
produced signals.

Figure 20. Custom needle recording setup used in the experiment to get basal signals
from an anesthetized mouse.
After recordings were taken from the custom needles, the recording electrode was
switched to a 0.5 MΩ commercial platinum iridium electrode from Microprobes, where
the electrode details are shown in Figure 21.

Figure 21. Microprobes recordings electrode that was used to compare to custom
needles in an anesthetized mouse.
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The electrical setup was the same for the Microprobes recordings as the custom
design needles. One recording electrode was placed at the same location in the scWAT,
and the other recording electrode placed in the tail, as detailed in Figure 22. The
Microprobes for Life Science is a company that focuses solely on neural microelectrodes,
needle arrays, and more. The needles from Microprobes are distributed worldwide for
neural recordings, so these electrodes were selected as a comparison to check the quality
and reliability of signals from the custom needles.

Figure 22. Microprobes setup showing the two differential recording electrodes, with one
in the tail that stayed constant throughout the experiment. The other needle was switched
with the custom needles for comparison.
The Microprobes needles used in this experiment are not beveled like the custom
needles are, so inserting them into the mouse tissue was much more difficult. Mouse skin
is very flexible, so upon insertion of the needle, the skin had to be pulled quite taut for the
needle to even slightly penetrate the skin. The custom electrodes are three-beveled
needles, which makes insertion into the tissue much easier. As a result, comparing
electrical recordings from these two needles is difficult, given the Microprobes needles
may not have even penetrated the tissue. This is a consideration that is important to
consider for future iterations of the designed prototype, given that beveled needles are
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much easier to work with compared to already available needles. The design, then, should
incorporate beveled needles when being put into an array to record electrical signals
faster and with more ease.

V. Natus and Custom Needle Basal Recordings in Anesthetized Mouse
An important aspect of the design platform is to make sure the custom needles
that will be used will be comparable to other needles, and yield results like what one
would expect. The objective of this experiment was to compare the feasibility of
collecting basal recordings from a set of commercially available needles to the custom
needles in an anesthetized mouse. Natus needles are currently used in nerve conduction
velocity tests, so they are a well-established comparison. This comparison between the
two needle types was done in three different tissues to determine if there are any
differences between the two needles, or any differences between tissue types. The tissue
types tested for each needle was the scWAT, muscle tissue, and the paw. Subcutaneous
white adipose tissue and the paw are two areas that will be tested in the future with the
first fully developed prototype because these two areas are prone to peripheral
neuropathy. A sample of the electrical setup in the scWAT tissue is illustrated in Figure
23, where the custom needles are inserted into the tissue.

Figure 23.Sample image from the experiment tested different tissue types with custom
needles inserted in the scWAT.
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Electrical signals from the muscle were tested in the experiment to compare
neuromuscular junctions between needles. The neuromuscular junction is a very wellstudied and well-understood electrical signal, so relating signals between the electrodes
would be suitable. Another purpose of this experiment was to further reduce noise levels
inside the faraday cage, as this is one of the most critical aspects when recording from
nerves. The neuromuscular junction, then, would ideally give insight on how much noise
must be further tested and reduced.
From this experiment, it can be concluded that both the Natus needles and the
custom needles are similar in how easy they are to work with. The custom needles, as
previously mentioned, pierce the skin fairly easily. The Natus needles pierced better than
previously used commercial electrodes, but still not as well as the custom needles. The
recordings that were collected during this experiment exhibited sinusoidal noise from the
environment. Therefore, this experiment was another attempt to further reduce this noise
from the signals to clearly detect an action potential.

VI. Invertebrate Leg Test to Compare Signals with Custom Needles
(experiment conducted by Brooke Villinski using the developed protocol)
Crickets are another well-established nerve model, similar to the horseshoe crab
used in previous experiments. Due to a shortage of horseshoe crabs at the time of the
experiment, crickets were used to test the custom needles compared with the Natus
needles. Crickets were used due to simplicity, but also because they are inexpensive and
readily available. The cricket as a neurophysiology model works by external sensory
structures, called cerci. The cerci are like antennae and can be mechanically stimulated to
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produce action potentials. Mechanically stimulating nerves can be done in many ways,
some of which include vibrations, pressure, and touch.36 For the purposes of comparing
the custom needles to commercial needles, this factor was useful to not have to rely on
the BIOPAC software for stimulation, but also to simplify the experiment’s required
technology.
Based on the procedure adapted from Dagda et. al., a cricket leg test was
conducted to compare the two needles. The recording electrode was inserted in the coxa,
and the ground was in the tarsus; these are two of the four segments of the cricket leg.
The cricket leg was mechanically stimulated with a blow of air from the experimenter.
The experimental setup for the Natus needles, which was similar to the custom needles, is
illustrated in Figure 24, where the electrode positions in the cricket leg are shown.

Figure 24. Experimental setup for the cricket leg test with the Natus commercial
electrodes pictured. The nerves were stimulated mechanically, with the recording
electrode in the Coxa and the ground in the Tarsus. Reproduced from Brooke Villinski.
The overall purpose of this test was to relate the results with the Natus electrodes
versus the custom electrodes as a “first pass” to compare recording performance. The
results from this experiment, are detailed in Figure 25, where Figure 25A is with the
Natus needle and Figure 25B is with the custom needle. The blue line indicates the start
of stimulation, which is why there is an increase in signal following it.
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Figure 25. Results collected from the cricket let experiment with A) a Natus electrode,
and B) a custom needle. The noise levels are comparable between the two needles.
Reproduced from Brooke Villinski.
From this experiment, it can be concluded that the noise levels are comparable
between the two, averaging about 12mV for both; this could indicate the needles behave
similar in the tissue. For the custom electrode, the response after stimulation is larger.
This could be because the custom needles are truly more sensitive than the commercial
comparison electrode. However, it should be taken into consideration that the stimulation
during this experiment was fairly uncontrolled. The puff of air could have been stronger
for the test with the custom electrode, which could have stimulated more nerves and thus
increased the resulting signal. As a result, for this test, a good comparison of the
recording performance is the signal noise amplitude to show similarities in needle
characteristics such as resistance and conductivity. The signal noise amplitudes are
comparable between the two needles, which was a first pass to ensure the custom needles
work as well or better than commercially available nerve conduction study electrodes.
Therefore, more tests with a mouse can be done to further validate the custom needle
electrodes given that they are currently not used for nerve studies.
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VII. Sciatic Nerve Stimulation in an Anesthetized Mouse
(experiment conducted by Brooke Villinski using the developed protocol)
Before recordings are taken from the scWAT and paw, areas of the mouse that are
not widely studied for nerve conductance, well-studied areas were ideal to start with
officially comparing the custom needles with commercially available electrodes. In this
experiment, the mouse’s sciatic nerve was exposed and the custom needles and Natus
needles were both used to take recordings using this well-studied nerve being stimulated.
Single needles were used as opposed to needles being in an array, and the ground
electrode was inserted into the tail. The sciatic nerve was stimulated with a Natus needle
for both recording electrode types, and recordings with both the Natus needles and
custom needles were taken from the plantar paw with the ground electrode in the tail. The
purpose of this experiment, like previous experiments, was to compare recordings in a
mouse between the custom needles and well-established needles.
This was the first experiment from an anesthetized mouse that clean action
potentials were able to be distinguished from the recordings because the noise level issue
had been mitigated. The mouse was stimulated with 50mV, and the amplifier was set to a
200x gain. The stimulation was tested prior to testing the needles in the mouse tissue to
ensure stimulation was actually occurring. Figure 26A shows the signal from the Natus
needle recordings, and Figure 26B shows the recordings taken with the custom needle
electrode. The blue line indicates the time of stimulation, which creates the large increase
in signal. The drop in signal shortly after is from the differential amplifier, and the
following rise in signal is a compound action potential (CAP), indicated in the figure.
CAPs are the summation of multiple different action potentials as it is an extracellular
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recording, which makes sense in the context of the recordings taken. The amplitude and
shape of signals are very similar between the two electrodes, which was a positive
outcome given that the custom electrodes are not typically used for nerve recordings.
CAP

CAP

Figure 26. Action potentials recorded from the experiment. A Natus electrode was used
for stimulation, indicated with the blue line, and the recording electrodes from A) Natus
needles and B) custom needles. The signals are very similar between the two needles.
Adapted from Brooke Villinski.
Another recording that was taken from this experiment is testing a custom needle
inside an array. The same setup was used with the Natus needle in the sciatic nerve for
stimulation, but the recording custom needle electrode was inserted within an array to
ensure the array components did not affect signals. Figure 27 is sample data from this
experiment, where the blue line again indicates the time of stimulation. A similar CAP is
observed that is similar in shape and size to the standalone custom needle in Figure 26B.
CAP

Figure 27. Action potential recorded after stimulation with a custom needle within an
array to determine if signals are affected when inserted into the array. The signals of the
standalone needle and the custom needle are comparable. Adapted from Brooke Villinski.
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Overall, from this experiment, it can be concluded that stimulated recordings can
be taken from an anesthetized mouse, and the signals between commercially available
needles and the custom needles to be used in the future array are comparable.
Additionally, the needle array itself does not affect the quality, shape, or amplitude of
signals using the custom needles.

VIII. Stimulation of Anesthetized Mouse with a Functioning Array
(experiment conducted by Brooke Villinski using the developed protocol, array designed
and printed by Julia Towne)
The previous experiment tested a working protocol with minimal signal noise to
stimulate an anesthetized mouse. The next step in validating the array concept is to test
recordings from multiple needles held in the array. A similar prototype that was used in a
previous experiment in testing the array was used where nine electrodes are used with a 2
mm needle penetration depth. The needles were arbitrarily numbered, and one electrode
was used for stimulation. Recording pairs within the array were grouped to evaluate the
quality of signals in an array, as indicated in Figure 28.

Figure 28. Schematic detailed the recording pairs and the stimulation electrode where
differential recordings were taken in the experiment. Reproduced from Brooke Villinski.
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Essentially, the goal of this experiment was to record four differential electrode
pairs and to stimulate with the ninth needle in an array. The ground electrode was placed
in the tail, and the needle array was inserted into the shaved scWAT tissue. A printed
circuit board (PCB) was used to wire the electrodes to the amplifier to make handling the
array with the mouse easier in future experiments. The PCB with the array in the scWAT
of the mouse is illustrated in Figure 29, again with the differential pairs indicated by
color.

Figure 29. Array setup for the experiment to record from four differential pairs with a
PCB board in a needle array. The mouse was anesthetized and recordings taken from
each of the color-indicated recording pairs to determine if array recordings are possible.
Reproduced from Brooke Villinski.
The results from the experiment are encouraging for pursuing recordings with the
selected custom needles. Sample recordings from all differentials are detailed in Figure
30, with the blue line indicating the stimulation time. The large spike followed by the
large drop in signal is due to the stimulation and the differential amplifier; however, the
increase in signal after are compound action potentials. The blue and pink electrode pairs
closer to the stimulation needle, aside for the red pair, show higher signals compared to
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the green pair that is further away from the stimulus. This is what one would expect given
that needles further away from the stimulation have more distance to lose signal to the
surroundings. The green pairs in the array could be too far away from the stimulation
needle to yield an action potential from surrounding nerves; the needles in future
iterations could be closer together to determine the maximum amount of distance
between needles to still get meaningful recordings.

Figure 30. All recording data collected from the needle array experiment. Differential
pairs are indicated by color. As the distance from the stimulation electrode increases, the
CAP signal decreases, as expected. Reproduced from Brooke Villinski.
There are several different factors that could have affected the results for the red
differential pair. The red differential pair was close to the stimulation needle, so it is
possible it was along the same nerve bundle. This could have affected the results of not
obtaining an action potential by being oversaturated with the stimulation voltage.
Additionally, it is possible these electrodes were not fully penetrating the tissue, so the
stimulation response from the nerves in this area was not captured. However, despite this
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discrepancy of this differential pair, from this experiment, it can be concluded that
recording from an array is possible. The overall magnitude of measured compound action
potentials decreases the further away from the stimulation needle, as expected, so more
experiments can be conducted to further push the progress of a longitudinal study of
diseased mice.

Summary of Results
From the series of experiments conducted thus far, several critical conclusions
were made. First, much has been learned about BIOPAC and what the final needle array
will look like. In terms of needle dimensions, the needles should be put as close together
as possible to make the overall array smaller. A rod in the center of the array to apply
constant pressure is unnecessary, but the idea of a holder for the needles to sit in is
important. If the needle array is simply just a holder for the needles, then the array can be
sanitized and used many times simply by just switching out the needles. Additionally,
because of the needle holder, a cap to cover the needles is another design aspect that
should be considered so the electrodes do not fall out of place. More dimensions of arrays
should be tested to further optimize the shape and usability for a final prototype.
Furthermore, protocols and familiarity with new hardware and software had to be
established. The BIOPAC software and hardware was selected due to its reproducibility
and sensitivity, as well as its broad range of capabilities and features. However, BIOPAC
has not necessarily been used for the purpose of recording from small nerve fibers, so
limits of sensitivity had to be configured. Detection limits and sensitivity of the
amplifiers are important when considering the unknown size of action potentials that will
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be collected from the peripheral areas. Understanding how the amplifier and detectors
function, as well as the types of signals they collect, will be important downstream in the
process to compare nerve signals between mice and between a diabetic and healthy
mouse. From this project, working BIOPAC hardware and software protocols have been
developed and tested, so both basal and stimulated recordings from mice are possible.
More work needs to be done to establish an optimized design, and many things
must be considered when designing the device, including constraints in 3D printing
capabilities, dimensions of the needles, the electrical characteristics of the needles
themselves, and more. Most of the start of this project has been developing protocols to
use the software and hardware to record signals, as well as comparing needles and array
dimensions. This mostly includes testing more 3D printed arrays and looking more into
how recordings from a needle array will be done. A couple of arrays were tested as the
first attempts to do so, but more should be tested to optimize the design. In one
experiment, one needle was used as a reference electrode, so this is something that can be
incorporated into future array recordings. The distances between needle electrodes will be
important for analyzing data and understanding the electrical signals that are collected,
too, as the signals change with distance. Overall, before a longitudinal study is
conducted, more needle arrays should be tested to verify and optimize the device.
Another aspect of the platform is determining how the data will be used and what
measure will be best suited to comparing electrical signals. In nerve conduction studies,
typically the nerve conduction velocity and the nerve amplitude voltage are used. These
measures could work but incorporating them into the developed system to establish
baselines and eliminate noise from the signals will require additional investigation.
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Other small portions of the project include tissue staining and imaging familiarity.
The Townsend Laboratory had never used the Luxol Blue stain before, so after receiving
this stain, part of the project to design this platform was to develop a procedure for
staining the tissues to look at myelinated nerves. To do so, several attempts were made
with different incubation times and tissue types with the stain to optimize and then image
with brightfield microscopy. Furthermore, as the device will eventually develop into a
startup company, several Maine Innovation, Research and Technology Accelerator
(MIRTA) meetings were attended. These meetings focus on commercialization,
understanding the consumer and audience, as well as outreach to establish an effective
startup company and device from a business perspective.
Overall, the objective of this project was to start the process of developing a
platform for creating a device to detect peripheral neuropathy earlier than it currently is.
Many protocols were established and optimized in order to become familiar with
hardware and software needed to record electrical signals. Additionally, needle
prototypes were tested, and several attempts were done to characterize the needle’s
properties. Determining an optimal needle and array dimensions are things that are in
progress for a final prototype of a design. The work conducted and illustrated in this
thesis have provided a way to collect signals, an attempt to understanding the signals, and
provided insight into what aspects and constraints will be in the design of the device.
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DISCUSSION
There is an increasing need for peripheral neuropathy detection in a clinical
setting. The growing obesity epidemic has made nerve death at the limbs an increasing
health concern that holds much importance worldwide. The eventual goal of the project is
to create a device to ultimately detect peripheral neuropathy sooner than it is currently in
the clinic, but this is an iterative process where many things must be considered. The
protocols and experiments conducted thus far for designing the platform to do so are just
the first steps in the process to create a working device. The design of the device will
incorporate a needle array and a longitudinal study of mice with diabetes will assess the
quality of this array in comparison with other methods.
The recordings that are typically conducted in both mice and humans are those
from large nerves, such as the sciatic and the sural nerve. Not many individuals have
attempted to record from small nerve fibers in areas such as the paw, but there is
comparable literature for recording in an array in these larger areas of the peripheral
nervous system. With standard-of-care devices and techniques, and even typical nerve
conduction studies, the designed device will be comparable. Similar recordings and
measurements are taken, as particular action potentials are distinguished in recordings
after stimulation with the custom needles. Diabetes can be diagnosed with a NCV study
with measurements such as the SNAP amplitude given that nerve stimulation induces an
action potential of a given magnitude, and such can be compared to a healthy
individual.32,37 As a result, the designed device is comparable as the action potential
amplitudes acquired can be compared in a similar fashion to NCV studies, so a diagnosis
between healthy and diseased individuals is possible.
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In addition, it was proven that muscle tissue can be stimulated and recorded from
with the custom needles. Another aspect of the standard of care for diagnosing peripheral
neuropathy refers to the CMAP.37 Compound action potentials were collected in the set
of experiments and muscle tissues were target tissues because they are so well
understood. Although the neuropathy is far along by the time it reaches the muscles, in
the initial stages of the device for proof-of-concept, it is critical to compare the CMAP
amplitudes recorded from the custom needles to those taken from commercial electrodes,
such as the Natus needles that are used in nerve conduction studies. This comparison
would yield similar data, as recording components thus far are comparable to data
collected based on the diagnostic standard of care of peripheral neuropathy.
In addition to being comparable to the standard of care for diagnosis, there are
researchers working to record from a needle array. Particularly, some of these electrodes
that record from peripheral areas are “cuff electrodes”; essentially, there are microneedles
or a conductive pad that is encompassed in a cuff that can be wrapped around a wrist,
ankle, arm, etc. However, maintaining the positioning of these electrodes is an issue for
sustained recordings, and there are sensitivity challenges.38 Compared to these cuff
electrodes, although desirable due to ease of use and ability to customize, the designed
device would likely serve a similar function but improve on areas the cuff electrodes fall
short in. For example, when using standard NCV study electrodes such as the Natus
needles, similar sensitivities and noise levels were recorded between the commercial and
custom needles. The Natus needles are more sensitive than cuff electrodes because of
their overall purpose, and because the custom needle arrays are comparable to the Natus
needles, the custom needle array design improves sensitivity while still being easy to use.
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As a result, the custom needle array would be the middle ground between cuff electrodes
that are not sensitive enough and the NCV needles that are painful and invasive.
There are a variety of flexible microneedle arrays depending on the fabrication
material, and cuff electrodes are just a subset of such. Specifically, flexible microneedle
arrays are used for at-home bio-signaling; these signals include other standard of care
measurements for diagnosing peripheral neuropathy, like an electromyogram. A benefit
of flexible microneedle electrodes not positioned as a cuff is for better electrode
positioning and stability. These electrode arrays can be bent in any shape to conform to
the subject’s skin which enhanced electrode penetration.39 The designed device thus far is
made of rigid 3D printed materials, but making the array flexible is a potential
improvement for the future. If the array backing for the custom device is flexible, this
could allow for better recordings to be taken given, for instance, the curvature of the foot.
A cuff electrode would not be suitable for the tapered shape of the foot, but a flexible
electrode would morph to the curvature of the ball of the foot for earlier detection of
nerve malfunction.
Another aspect of microneedle electrode arrays that are currently used have a
varying needle heights. The Utah Slant Electrode Array features microneedles with a
slant to penetrate different depths of tissue, as shown in Figure 31.40

Figure 31. Utah Slant array highlighting the differences in needle heights. Reproduced
from Ref [40].
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With this slanted electrode setup, peripheral nerves are targeted. However,
experiments with this electrode focus on the sciatic nerve and not the areas the custom
device will focus on such as the paw and scWAT. In studies with the slanted array, there
is stimulation over a time course to track the threshold measurements after insertion.40
This is comparable to the custom needle array as similar recordings will be taken with
stimulation. From these commercial electrode arrays, the potential for different needle
heights could be proven beneficial. If the needle array could penetrate the skin layers, the
underlying adipose, and then muscle tissue, the progression and severity of neuropathy in
the area could be evaluated. Instead of one electrode height where the electrodes
penetrate one tissue type, incorporating different needle heights would allow for
recordings from each tissue for a more well-rounded diagnosis. Peripheral neuropathy
moves from the skin inward, and neuropathy is evident in the adipose tissues.13 Slanted
needle heights in the custom device to penetrate the underlying adipose tissue, as well as
other tissue types, would improve the overall quality of the device and understanding of
the disease in general.
An important component to that makes microneedle arrays desirable is the ability
for these electrodes to be available for at-home use. With an increasing aging population,
microneedle arrays will hopefully reduce the need for long-awaited doctors visits, but
also reduce preparation time for any gel or lubricants for larger, more invasive
needles.39,41 The designed microneedle array will be easy to use and implement for an
individual and be much less invasive. The goal is to make custom design able to fit in the
palm of one’s hand so it would be portable, lightweight, and efficient. These standards
are crucial for microneedle arrays as the small size and scale make these arrays desirable.
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To compare in a competitive commercial market, the device must be at least the same
size, and if not, improve on weakness areas, such as the addressed sensitivity.
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FUTURE DIRECTIONS

Once a working prototype is established, there is a clear direction moving forward
on a longitudinal study to track the progression of diabetic mice compared to healthy
mice. Young mice will be used, and the disease progression will be tracked using many
different diagnostic methods. As previously mentioned, the Townsend Laboratory has
established both a genetic and environmental mouse model of mice that will develop
peripheral neuropathy. Therefore, starting out, young mice that will develop neuropathy
either by genetics or by environmental causes, like a high fat diet, will be compared to
healthy mice.
There are several different methods that will be used to track the progression of
disease. A Von Frey test is one currently used in the Townsend Laboratory and in the
clinical diagnosis of neuropathy. It involves filaments with varying forces that are
pressed against the mid-plantar surface of the mouse’s paw. The amount of force and the
time the animal takes to react to the force is used as a relative measure of neuropathy.
The Townsend Laboratory frequently uses this method for neuropathy progression and
diabetic studies, so standard and diseased baselines with this test are known. As a result, a
Von Frey test will be used in a series of others to track the progression of disease.
Protocols that were established in this work for a cold plate and acetone test are
other measures of neuropathy that will be utilized. A cold plate and acetone test are like
the Von Frey, where the animal’s reaction to each is recorded. Any delayed or unusual
responses would be indicative of some extent of nerve death. Each of these behavioral
tests—Von Frey, cold plate, and the acetone test—will be used to compare to the
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electrical signals obtained from these mice. Ideally, these tests, in conjunction with
electrical signals from the developed protocols, would be conducted once a week over the
course of several weeks. Additionally, some mice will be euthanized throughout the study
and their tissues collected as a small portion of the project was to become familiar with
different staining techniques. Luxol Blue is a myelin stain, so this could track the
progression of demyelination that occurs with peripheral neuropathy. The myelin that
surrounds some nerves will stain blue, and the surrounding tissue will be a clear white, as
detailed in Figure 32, which shows an image stained with Luxol Blue from the scWAT.

Myelinated nerve

Blood vessel

Figure 32. Image from the scWAT tissue of a mouse stained with Luxol Blue. Both blood
vessels and myelinated nerves can be distinguished in tissues stained with Luxol Blue.
PGP9.5 is another stain that will be used after tissue collected. PGP9.5 is a panneuronal antibody stain, so all nerves in the tissue will be stained, as shown in Figure
33.42 As a result, nerve death can be compared at different stages of disease with the
amount of stain that is imaged. The two stains, PGP9.5 and Luxol Blue will then yield a
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full picture at the tissue level of the underlying adipose nerves. The results from the
staining can then be compared to the electrical recordings and behavioral tests to give a
functional, behavioral, and pathological comparison of peripheral neuropathy.

Figure 33. PGP9.5 antibody pan neuronal marker. Reproduced from Ref [42].
In the near future, a longitudinal study will be conducted using mice as a model of
disease to identify the sensitivity and quality of the designed device as a diagnostic tool.
The work conducted is part of a bigger picture to attempt to diagnose peripheral
neuropathy earlier in the clinic by using a less invasive and painful method. In doing so,
hopefully the peripheral neuropathy worldwide presence can be better understood,
diagnosed, and treated, and diabetic individuals can have a better quality of life.
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APPENDIX B
BIOPAC Recording Protocol
BIOPAC SOP
EM & JWW
Updated July 23rd, 2019
SECTION I – Set-up and Recording
White cord: stimulating needles, which are connected to black leads
Red alligator hook leads: differential recording needles, labeled with “+1” and “-1”
Software Start-up:
1.
Turn on VisionTek external USB connector (back right).
2.

Turn on laptop (right) with usual Townsend lab password.

3.

Insert teal BioPac USB into VisionTek USB reader.

4.

Turn on BioPac on MP160 (in the back on BioPac hardware all the way to the left)

5.

When computer is on, open AcqKnowledge icon on desktop.

a.
NOTE: if at this point an error occurs, try bypassing the VisionTek by
plugging the black BioPac USB cord and teal BioPac USB directly into the laptop.
Restart BioPac and software.
6. Adjust left most amplifier settings (subject to change) - *indicated on amplifier itself
Basal Recordings
Stimulation Recordings

7.

1000x gain

200x gain

3kHz LP

3kHz LP

ON

ON

0.5 Hz HP

0.5 Hz HP

Select the “Create new experiment” and then open an existing graph template.

Examples of existing templates:
a.

Basal Recordings: “2channelMCE100C_test2”
i.

b.

NOTE: there is no “stimulation” in the name

Stimulation: “2channelMCE100C_Stimulation_0.2Volts_2msec pulse
i.

NOTE: stimulation voltage and length of stimulation pulse can be
modified after opening existing graph template – See Section 2
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8.

Acquiring Recordings:
In the Faraday cage, for recordings, open the alligator hook leads and clamp in the
desired electrodes

9.

Using the manipulator, insert the electrode into the tissue.

10.

Insert the other red differential wire with the desired electrode into the sample.
a.

11.

NOTE: the +1 lead and -1 lead labeling does not matter for which
electrode is which because the amplifier will just measure. These red
leads with +1 and -1 are RECORDING needles, so they will be needed
for basal and recording needles.

If stimulating, follow the thicker white cable (looks like a phone jack) into the cage
from the amplifier. Insert the black stimulation lead labeled “signal,” and this
electrode is where stimulation will come from.
a.

12.

NOTE: the green wire that extends from the larger white wire is the
stimulation ground. Only use if necessary, i.e. signal is noisy and
trying to reduce noise by trial and error.

Insert the black lead from the cage labeled “ground” into an appropriate position
on the sample.

13.

Close the Faraday cage if possible. Press “Start” (top left of software) if needles
and electrodes are accurately placed.

14.

Settings (i.e. high/low pass filters, electrode positioning) can be changed
throughout, but the times where things are changed should be recorded. There is a
stop bottom where start in the top left was clicked that will stop collection if
necessary.

15.

Save the data as follows:
a.

Basal recordings
“INITIALS_date_file description”
ex. “EM_14dec2019_2 needle recording array dead mouse”

b.

Stimulation
“INITIALS_date_file description
ex. “EM_14dec2019_BD needle stimulation dead mouse”
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16.

After recording and saving data, if conducting another experiment, close out of
AcqKnowledge and reopen the GTL template.

Close Out of Software:
17.
Close AcqKnowledge icon
18.

Eject BioPac teal USB on the laptop and remove from VisionTek.

19.

Turn off BioPac MP160 hardware, VisionTek USB reader, and laptop.
SECTION II - Manipulating Software and Tips

1.

Modifying Stimulation and Pulse:
Select MP160àSet up data acquisitionàstimulation (top left of software)

2.

Change the voltages and the timing in between intervals as needed.
a. NOTE: for changes to be applied the run must be stopped and
started again
b. Below are two examples of settings
Segment # Voltage (V) Time (ms)
1

0

100

2

0.2

2

3

0

100

4

0.2

2

5

0

100

Example of dual 0.2 V, 2 ms pulses with alternating 100 ms and 200 ms
delays. This is what was being used previously.
Segment #

Voltage (V)

Time (ms)

1

.05

2

2

0

300

3

0

0

4

0

0

5

0

0

Example of what yielded positive results for sciatic nerve in mouse. A single
0.05 V, 2 ms pulse followed by a 300 ms delay.
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3.

Save as template with a new name with the given settings that were changed.
a.

For example, include the stimulation and voltage magnitude in
the name, i.e.
“2channelMCE100C_Stimulation_0.05volts_2msec pulse”

1.

Modifying Scales:
Adjusting Voltage Scale (y-axis)
a.

Double-click y-axis

b.

Popup screen will appear.

c.

Adjust scale anywhere from 1-15 V depending on size of signal

and or noise.
2.

Adjusting Time Scale (x-axis)
a.

Double-click y-axis

b.

Popup screen will appear

c.

Adjust time to 200ms to distinguish wave
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APPENDIX C
COLD PLATE PROTOCOL
Cold Plate Test Protocol (Thermal Allodynia)
Adapted from Van der Waal et al. 2015
EM Updated February 2019
1. Cover the bottom of the Von Frey apparatus with aluminum foil and tape to the
sides of the apparatus. Ensure the mouse’s feet can still be seen past the tape and
aluminum foil.
2. Determine the number of experimental subjects and place each mouse into its own
area within the Von Frey apparatus. Allow acclimation for 15-20 minutes.
a. NOTE: Make sure to properly label each compartment with the necessary
mouse information (i.e. any identifying markers: mouse ID, ear punch,
sex, etc.)
3. Place the entire Von Frey enclosure into a bucket containing ice with a thin layer
of aluminum foil across the top of the ice and record the time.
4. Using a stopwatch, observe and record the time at which any of the potential
reactions listed below occur, being sure to record any corresponding intensities
for each reaction:
a. Lifting of the paw or on hind legs
b. Scratching of the paw
c. Touching side of hip or paw depending on side of paw administration
5. Record the time that the cold plate reaches 2-2.5 ºC.
6. Record the amount and intensity of each behaviors exhibited over a period of 4
minutes.
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Cold Plate Test Data Recording Template

Figure 34. Cold plate test data recording template. There are areas for specific information
about the study, such as the mouse ID and project. The time when the mouse was put on the cold
surface is recorded, and the time when the cold plate reaches the proper temperature. There are
time boxes for the lifting of paw/on two feet behavior that can be shaded accordingly when the
mouse performs that behavior. Other times for other less frequent behaviors can be recorded, as
well as any observations. For analyzing the data, the total latency behavior time is used.
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Acetone Touch Test Protocol
Neuropathy Acetone Test
Adapted from Vissers, et. Al (2005)
EM Updated February 2019
1. Determine number of experimental subjects and place each mouse into its own
area within the Von Frey apparatus
a. NOTE: Make sure to properly label each compartment with the necessary
mouse information (i.e. any identifying markers: Mouse ID, Ear Punch,
Sex, etc.)
2. A total of 12 mice may be tested at once, but be sure to allow each mouse
approximately 15-20 minutes to acclimate to the mesh flooring before testing
a. NOTE: Mice have acclimated when excessive movement and grooming
have ceased.
3. Set up video camera so the mice can be seen
4. Fill a 1 mL Tuberculin syringe with acetone and gently push the syringe until a
small bubble forms at the top of the syringe
5. Start recording on the camera. Gently apply the acetone to the plantar surface of
the hind paw (see diagram below), making sure to only touch the mouse with the
acetone bubble formed at the top of the syringe.

Mid-Plantar Surface Target

6. Observe each mouse for any of the following acetone evoked behaviors:
a. Paw elevation
b. Flinching
c. Licking
d. Scratching
7. Using the video camera, record how long these acetone evoked behaviors are
present for a minimum of 0.5 seconds (for the brief normal response) to a
maximal cut off of 20 seconds (Choi et al. 1994)
a. NOTE: Time 0 begins when the acetone is applied and stops when the
behaviors have ceased
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